MyChesCo on MSN15h
Palvella Therapeutics Reports Promising Results for QTORIN Rapamycin in Treating Rare Genetic DiseaseWAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has announced positive outcomes from a Phase 2 study evaluating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback